Minerva Neurosciences, Inc. NERV
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | 285.72% | -- | -- | -- |
| Gross Profit | -- | -285.72% | -- | -- | -- |
| SG&A Expenses | 66.41% | 349.40% | 10.58% | -22.58% | -14.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 215.41% | 327.16% | 10.16% | -34.86% | -46.25% |
| Operating Income | -215.41% | -327.16% | -10.16% | 34.86% | 46.25% |
| Income Before Tax | 636.01% | -3,241.44% | -6,540.16% | -112.19% | 60.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 636.01% | -3,241.44% | -6,540.16% | -112.19% | 60.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 636.01% | -3,241.44% | -6,540.16% | -112.19% | 60.42% |
| EBIT | -215.41% | -327.16% | -10.16% | 34.86% | 46.25% |
| EBITDA | -215.49% | -327.28% | -10.16% | 34.87% | 46.26% |
| EPS Basic | 182.97% | -476.16% | -4,420.61% | -112.19% | 60.42% |
| Normalized Basic EPS | 187.07% | -476.12% | -4,419.95% | -112.19% | 60.42% |
| EPS Diluted | 67.97% | -476.16% | -4,420.61% | -112.21% | 60.42% |
| Normalized Diluted EPS | 151.28% | -476.12% | -4,419.95% | -112.19% | 60.42% |
| Average Basic Shares Outstanding | 515.66% | 480.00% | 46.89% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 945.11% | 480.00% | 46.89% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |